CD4 and cancer: Lan et al. [27] further reported that the immunotherapy of DC-CIK cells significantly increased the proportion of CD3+ T cells, CD3+ CD4+ T cells, and the ratio of CD4+/CD8+ T cells and decreased the CD3+ CD8+ T cells in malignant tumors.